High grade dysplasia: surveillance, mucosal ablation, or resection?

Area of Science:

• Gastroenterology
• Oncology
• Surgical Oncology

Background:

• Barrett's esophagus is a premalignant condition linked to chronic gastroesophageal reflux.
• High-grade dysplasia (HGD) in Barrett's esophagus is considered the final step before esophageal cancer development.
• Current management strategies for HGD in Barrett's esophagus lack universal consensus.

Purpose of the Study:

• To evaluate the efficacy and outcomes of different management strategies for high-grade dysplasia in Barrett's esophagus.
• To compare endoscopic surveillance, mucosal ablation, and esophagectomy for treating HGD in Barrett's esophagus.
• To determine the optimal treatment approach balancing efficacy, patient risk, and long-term outcomes.

Main Methods:

• Review of existing literature and clinical practices regarding HGD management in Barrett's esophagus.
• Analysis of outcomes associated with endoscopic surveillance, mucosal ablation, and esophagectomy.
• Consideration of patient factors, including operative risk, in treatment selection.

Main Results:

• Endoscopic surveillance for HGD in Barrett's esophagus faces challenges including impracticality, cost, sampling errors, and unproven effectiveness.
• Mucosal ablation is an emerging therapy but has limitations such as incomplete eradication, pseudoregression, and the need for ongoing surveillance.
• Esophagectomy, despite its invasiveness, demonstrates a low mortality rate and high 5-year survival, even in cases with unexpected invasive cancer.

Conclusions:

• Esophagectomy is advocated for eligible patients with HGD in Barrett's esophagus due to its curative potential and elimination of lifelong surveillance.
• Mucosal ablation may be a viable option for poor surgical risk patients, but requires further long-term follow-up data.
• The management of HGD in Barrett's esophagus necessitates careful consideration of individual patient factors and treatment risks versus benefits.